LLY

1,053.95

+2.58%↑

JNJ

213.94

+1.18%↑

ABBV

227.32

+1.73%↑

UNH

338.97

-0.71%↓

AZN

91.17

+1.54%↑

LLY

1,053.95

+2.58%↑

JNJ

213.94

+1.18%↑

ABBV

227.32

+1.73%↑

UNH

338.97

-0.71%↓

AZN

91.17

+1.54%↑

LLY

1,053.95

+2.58%↑

JNJ

213.94

+1.18%↑

ABBV

227.32

+1.73%↑

UNH

338.97

-0.71%↓

AZN

91.17

+1.54%↑

LLY

1,053.95

+2.58%↑

JNJ

213.94

+1.18%↑

ABBV

227.32

+1.73%↑

UNH

338.97

-0.71%↓

AZN

91.17

+1.54%↑

LLY

1,053.95

+2.58%↑

JNJ

213.94

+1.18%↑

ABBV

227.32

+1.73%↑

UNH

338.97

-0.71%↓

AZN

91.17

+1.54%↑

Search

Protagonist Therapeutics Inc

Avatud

SektorTervishoid

95.12 0.16

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

94.6

Max

95.92

Põhinäitajad

By Trading Economics

Sissetulek

-4.6M

-39M

Müük

-834K

4.7M

P/E

Sektori keskmine

136.742

77.671

Aktsiakasum

-0.62

Kasumimarginaal

-834.868

Töötajad

128

EBITDA

3.1M

-39M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

-6.09% downside

Turustatistika

By TradingEconomics

Turukapital

917M

5.6B

Eelmine avamishind

94.96

Eelmine sulgemishind

95.12

Uudiste sentiment

By Acuity

50%

50%

158 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Protagonist Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. okt 2025, 15:47 UTC

Suurimad hinnamuutused turgudel

Protagonist Therapeutics Leaps on Report of Possible J&J Deal

10. märts 2025, 13:59 UTC

Suurimad hinnamuutused turgudel

Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra

10. okt 2025, 15:13 UTC

Omandamised, ülevõtmised, äriostud

J&J, Protagonist Have Existing Ties -- WSJ

10. okt 2025, 15:13 UTC

Omandamised, ülevõtmised, äriostud

Protagonist Has Market Value Over $4B -- WSJ

10. okt 2025, 15:13 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson in Talks to Buy Protagonist Therapeutics -- WSJ

10. okt 2025, 15:13 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson in Talks to Acquire Protagonist Therapeutics, Sources Say -- WSJ

Võrdlus sarnastega

Hinnamuutus

Protagonist Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-6.09% langus

12 kuu keskmine prognoos

Keskmine 89.54 USD  -6.09%

Kõrge 115 USD

Madal 65 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Protagonist Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

13

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

43.62 / 44.27Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Weak Bullish Evidence

Sentiment

By Acuity

158 / 374 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
help-icon Live chat